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ABSTRACT
To further expand the limited multilocus sequence typing (MLST) database for Acinetobacter baumannii,
53 clinical isolates from various outbreaks in Europe and the USA, collected between 1991 and 2004, plus
the A. baumannii reference strain ATCC 19606T and 20 clinical Acinetobacter genomic species 13TU
isolates from the same period, were analyzed using a new MLST scheme based on fragments of the gltA,
gyrB, gdhB, recA, cpn60, gpi and rpoD genes. Data were compared with typing results generated using
pulsed-field gel electrophoresis (PFGE) and randomly amplified polymorphic DNA (RAPD)-PCR.
In total, 50 sequence types (STs) were distinguished among theA. baumannii isolates investigated, and the
MLST data were in high concordance with the PFGE and RAPD-PCR results. Only five clonal complexes
were identified by eBURST analysis, including the 21 STs listed in a previous study, suggesting high
diversity among the A. baumannii isolates. With one exception, there was no relatedness among isolates
from outbreaks in different countries (Europe) or regions (USA). No intercontinental spread was
revealed. Acinetobacter genomic species 13TU isolates could also be analyzed using the A. baumannii
MLST scheme (18 different STs) and could be distinguished from A. baumannii isolates according to
characteristic sequences. It was concluded that the MLST scheme provides a high level of resolution and
is a promising tool for studying the epidemiology of A. baumannii and Acinetobacter genomic
species 13TU.
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INTRODUCTION
Acinetobacter baumannii is a significant nosocomial
pathogen that especially affects patients with
impaired host defences in intensive care units,
and that has been implicated in severe nosocomial
infections, including bloodstream infection, pneu-
monia and meningitis, with mortality rates as high
as 64% [1]. Similar to methicillin-resistant Staph-
ylococcus aureus, major epidemiological features of
these organisms include their propensity for
clonal spread, their involvement in hospital out-
breaks, and their resistance to multiple antimicro-
bial agents [2–6]. Many recent outbreaks have
been caused by multidrug-resistant (MDR) strains
of A. baumannii and have occurred in intensive
care units where the extensive use of antibiotics
may have contributed to the selection of highly
resistant strains [7,8]. Currently, 10–33% ofA. bau-
mannii isolates are MDR [9,10], with increasing
resistance to the carbapenems being seen in
the last decade [8,11,12], leaving only limited
therapeutic options. A. baumannii, together with
three other closely related Acinetobacter spp.,
Acinetobacter calcoaceticus and Acinetobacter geno-
mic species 3 and 13TU, have been grouped
together in the ‘A. calcoaceticus–A. baumannii
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(Acb) complex’ because they are very similar
phenotypically and are often impossible to differ-
entiate [13]. A. baumannii and Acinetobacter geno-
mic species 13TU are responsible for most
nosocomial infections, while Acinetobacter geno-
mic species 3 is implicated less often in clinical
disease [14], and A. calcoaceticus is an environ-
mental organism that has been isolated rarely
from clinical specimens.
To investigate the molecular epidemiology of
A. baumannii, a variety of typing systemshave been
developed, including ribotyping [13,15], genome
analysis by selective amplified fragment length
polymorphism [4], pulsed-field gel electrophoresis
(PFGE) [15], randomly amplified polymorphic
DNA (RAPD) analysis [16] and infrequent-restric-
tion-site PCR [17]. Another possible approach
involves the use of multilocus sequence typing
(MLST). MLST is a highly discriminative typing
method that is based on the sequence comparison
of internal fragments of housekeeping genes. It has
been applied to a variety of bacterial pathogens,
including Neisseria meningitidis [18], Streptococcus
pneumoniae [19], S. aureus [20], Staphylococcus
epidermidis [21], Enterococcus faecium [22] and, most
recently, A. baumannii [23]. MLST provides a
powerful tool for global epidemiological studies
and studies of the population biology of bacterial
species. The MLST scheme for A. baumannii is
based on 305–513-bp sequences of the conserved
regions of seven housekeeping genes, i.e., gltA,
gyrB, gdhB, recA, cpn60, gpi and rpoD.
The present study was undertaken to further
evaluate the MLST scheme for A. baumannii, using
epidemiologically characterized A. baumannii iso-
lates, and to investigate whether the scheme could
also beused to type isolates belonging to the closely
related Acinetobacter genomic species 13TU.
MATERIALS AND METHODS
Bacterial strains
A. baumannii and Acinetobacter genomic species 13TU isolates
were collected between 1985 and 1998 from various hospitals
in Germany and other European countries, e.g. Belgium,
Denmark and the UK. In addition, A. baumannii blood culture
isolates recovered from patients in 49 medical institutions of
various sizes throughout the USA between 1995 and 1998
(SCOPE Project [24]) were analyzed. Epidemiological details of
the 74 isolates investigated have been described previously
[6,15,25] and are summarized in Table 1. Identification of
Acinetobacter spp. to the genus level was confirmed by the
transformation assay of Juni [26]. Speciation was performed
according to the simplified identification scheme of Bouvet
and Grimont [27], and was then confirmed by ribotyping and
amplified 16S rDNA restriction analysis [13,28]. On the basis of
preliminary typing results obtained with RAPD-PCR and
PFGE (see below), the 74 clinical Acinetobacter isolates (i.e. 53
A. baumannii isolates, the A. baumannii reference strain ATCC
19606T, and 20 isolates belonging to Acinetobacter genomic
species 13TU) were selected to represent outbreak-related (one
isolate ⁄ outbreak) and sporadic isolates from different coun-
tries in Europe and from different regions in the USA.
Epidemiological typing
The relatedness of all isolates was assessed using RAPD-PCR
analysis with two different primers (ERIC-2 and M13) and
Ready-to-Go RAPD Analysis beads (Pharmacia Biotech, Frei-
burg, Germany) as described previously [16]. Analysis was
confirmed using PFGE analysis of genomic DNA digested
with ApaI as described previously [6]. Fingerprint patterns
were compared visually and by Molecular Analyst software
(Bio-Rad Laboratories, Munich, Germany). Isolate relatedness
was assessed in accordance with published criteria [29], and
isolates for further analysis were selected on the basis of a
unique fingerprint pattern; i.e. all duplicate isolates with an
identical PFGE pattern were excluded. MLST analysis was
performed as described previously [23]. In brief, the sequences
of internal fragments of the citrate synthase (gltA), DNA
gyrase subunit B (gyrB), glucose dehydrogenase B (gdhB),
homologous recombination factor (recA), 60-kDa chaperonin
(cpn60), glucose-6-phosphate isomerase (gpi) and RNA poly-
merase r70 factor (rpoD) genes were determined. PCR condi-
tions comprised 2 min at 94C, followed by 30 cycles of 94C
for 1 min, 55C for 1 min and 72C for 2 min, followed by
2 min at 72C. Sequencing of internal fragments of c. 450 bp
was performed using an ABI Prism 3700 DNA sequencer
(Applied Biosystems, Foster City, CA, USA) with BigDye
fluorescent terminators and the primers described previously
[23]. Sequences were analyzed using the VectorNTI Software
package and were compared with the A. baumannii database
at the MLST website (http://pubmlst.org/abaumannii/). In
addition, all sequences were analyzed using the Sequence
Output and MEGA programs available from the MLST
website (http://www.mlst.net). For the current analysis, all
A. baumannii strains described previously by Bartual et al. [23]
were included. The relationship between A. baumannii se-
quence types (STs) was assessed using the eBURST program
available from the MLST website. Sequences of Acinetobacter
genomic species 13TU isolates were also analyzed using
Sequence Output and eBURST. The similarities between the
allelic profiles were analyzed by the unweighted pair-group
method with arithmetic averages (UPGMA), available in
MEGA suite program v. 2.1 (http://www.megasoftware.net).
To obtain the index of association (Ia), the Sequence Type
analysis and recombinational tests software package was used
(START v. 1.05, http://outbreak.ceid.ox.ac.uk/software.htm)
[30].
RESULTS
MLST results were obtained for all the A. bau-
mannii and all Acinetobacter genomic species 13TU
isolates included in this study. Since the original
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MLST scheme was evaluated for A. baumannii, no
database comparison was possible for the Acinet-
obacter genomic species 13TU isolates. To assess
the possibility of using the MLST scheme for
Acinetobacter genomic species 13TU, separate
analyses were performed for A. baumannii and
Acinetobacter genomic species 13TU isolates.
Overall, MLST analysis revealed 50 different
STs among 54 A. baumannii isolates and 18 differ-
ent STs among 20 Acinetobacter genomic spe-
cies 13TU isolates. In total, 65 novel STs were
detected, 47 for A. baumannii (designated ST-22
to ST-68) and 18 for Acinetobacter genomic spe-
cies 13TU isolates (designated ST-I to ST-XVIII).
The MLST data for all isolates were in high
concordance with the epidemiological typing
results generated by PFGE and RAPD-PCR
fingerprinting (Table 1). However, some
isolates with closely related PFGE patterns, e.g.
A. baumannii CGN-09 and ST-1650 [23], CGN-06
and ST-17093 [23], and Acinetobacter genomic
species 13TU isolates CGN-42 and CGN-50, had
different, although closely related, STs (single-
locus variants). No isolates with identical STs had
different PFGE patterns.
According to eBURST analysis, including the 21
STs described previously [23], only five clonal
complexes (CCs) were identified among A. bau-
mannii isolates from different outbreaks, with the
55 singletons (Table 2) suggesting high diversity
among the isolates. In addition, a founder could
only be identified for one of the CCs. The
population structure of A. baumannii, based on
the sample of isolates investigated, was calculated
using eBURST with modified settings. The Ia was
used to test for linkage disequilibrium among
alleles at the seven housekeeping genes. For all
A. baumannii isolates, the Ia value was 0.716
(expected variance = 0.655). Using only one rep-
resentative isolate for each ST, this value was
reduced to 0.546 (expected variance = 0.645).
Acinetobacter genomic species 13TU isolates
were investigated separately. In addition to 14
singletons, two CCs were identified. No founder
could be predicted for any of the CCs (data not
shown). The population structure of Acinetobacter
genomic species 13TU isolates was analyzed
using the same eBURST settings as those for the
analysis of A. baumannii. When eBURST was used
to analyse A. baumannii and Acinetobacter genomic
species 13TU isolates together, separation of the
species, as expected, was not possible. However,
there were no close relationships (e.g. single-locus
variants, double-locus variants, or triple-locus
variants) between A. baumannii and Acinetobacter
genomic species 13TU STs, and no CC contained
isolates of both species (data not shown). With
one exception, i.e. obviously identical strains from
Cologne, Germany (CGN-37) and Nottingham,
UK (CGN-77), no apparent relatedness among
isolates from different outbreaks was revealed. In
addition, no relationships among isolates from
different countries (Europe) or regions (USA)
were revealed, and no intercontinental spread
was revealed.
Upon comparison of the sequences of the
individual alleles of A. baumannii and Acinetobac-
ter genomic species 13TU isolates, certain parts of
the sequence were characteristic for Acinetobacter
genomic species 13TU and could be used for
species identification (Fig. 1). Acinetobacter geno-
mic species 13TU isolates also clustered sepa-
rately from the A. baumannii isolates. Clustering
based on the combined sequences of all genes is
shown in Fig. 2 (generated using the UPGMA and
Kimura pairwise distance method).
DISCUSSION
A. baumannii has a particular propensity for
nosocomial cross-transmission, and outbreaks
of MDR A. baumannii are being reported increas-
ingly [5,31]. The current study is the first to
apply the new MLST scheme for A. baumannii to
the epidemiological typing of isolates from a
wide range of hospitals and countries. This
MLST scheme was originally designed to inves-
tigate the molecular epidemiology of A. bauman-
nii, and has been validated for this purpose [23].
However, as A. baumannii and Acinetobacter
genomic species 13TU share the same clinical
and epidemiological characteristics and are
closely related phenotypically, 20 Acinetobacter
genomic species 13TU isolates were also
included to address the question of whether
the current MLST scheme could also be used for
studying the epidemiology of Acinetobacter geno-
mic species 13TU. Other species from the Acb
complex were not included because of their
lower clinical significance.
The present study identified 65 novel STs,
which can be explained, in part, by the fact that
this was the first study to use the scheme for a
broad range of isolates in the clinical setting,
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Table 1. Comparison of results obtained by multilocus sequence typing, pulsed-field gel electrophoresis (PFGE) and
randomly amplified polymorphic DNA (RAPD) for the Acinetobacter baumannii and Acinetobacter genomic species 13TU
isolates used in this study
Isolate
Original
designation Species
Outbreak
(Y ⁄N)
Origin
Year Country
PFGE or
RAPD profile ST Allelic profile
CGN-03 U-11432 AB Y 1991 Cologne, Germany Ga, XXIbb 16 10-12-4-11-11-9-5
CGN-04 St-16706 AB Y 1991 Cologne, Germany I, XXVIIIa 18 10-13-4-11-12-11-5
CGN-5a St-19001-I AB Y 1992 Cologne, Germany I, XXVIIIb 18 10-13-4-11-12-11-5
CGN-5b St-19001-II AB Y 1992 Cologne, Germany I, XXVIIIc 18 10-13-4-11-12-11-5
CGN-77 Multi 6 AB Y Nottingham, UK K, cc 19 1-14-3-2-2-9-3
CGN-37 V-11135 AB Y 1991 Cologne, Germany K, cc 19 1-14-3-2-2-9-3
CGN-06 M-8489 II AB Y 1991 Cologne, Germany L1, XXXIIIa 22 1-15-13-12-4-12-37
CGN-07 St-17108 II AB Y 1991 Cologne, Germany L1, XXXIIIa 22 1-15-13-12-4-12-37
CGN-81 Schneider 040 AB Y 1996 Cologne, Germany NT ⁄UP 23 1-1-1-1-1-28-10
CGN-18 PGS 9771 AB N 1990 Naestved, Denmark XI 24 1-1-22-1-4-20-16
CGN-48 M-6334 AB N 1991 Cologne, Germany NT ⁄UP 25 1-1-41-6-23-31-26
CGN-35 ATCC 19606 AB N 1911 Delft, The Netherlands XIII 26 1-10-36-22-20-4-24
CGN-09 V-16319 AB Y 1991 Cologne, Germany N1, IXa 27 1-12-15-2-2-3-3
CGN-55 Berlin 1-3809 AB Y 1996 Berlin, Germany NT ⁄UP 28 1-12-3-2-2-35-4
CGN-52 PGS 50853-82 AB N Denmark VII 29 1-12-3-28-2-29-4
CGN-56 Berlin 1-3740 AB Y 1996 Berlin, Germany NT ⁄UP 30 1-12-3-29-2-34-4
CGN-39 Remscheid AB Y 1998 Remscheid, Germany NT ⁄UP 31 1-12-39-25-21-3-25
CGN-44 M-7968 AB N 1991 Cologne, Germany XX 32 1-12-4-11-4-28-2
CGN-46 M-13546 AB N 1991 Cologne, Germany XIX 33 1-12-4-11-4-29-2
CGN-23 St-17306 AB N 1991 Cologne, Germany XXXIV 34 1-15-13-12-4-49-37
CGN-71 SCOPE 31 AB Y 1995 New York, NY, USA S-kd 35 1-15-2-28-1-41-32
CGN-74 SCOPE 37 AB Y 1995 Orlando, FL, USA S-l 36 1-15-2-28-1-44-32
CGN-15 V-12277 AB N 1991 Cologne, Germany XXXVI 37 1-19-21-17-1-18-14
CGN-19 PGS 10074 AB N 1990 Vejle, Denmark XII 38 1-25-23-6-4-21-17
CGN-20 W-8834 AB N 1991 Cologne, Germany XVII 39 1-26-24-1-4-3-10
CGN-53 PGS 10086 AB N 1990 Vejle, Denmark NT 40 1-3-6-1-4-34-10
CGN-30 M-12665 AB N 1991 Cologne, Germany NT ⁄UP 41 1-31-31-24-4-10-21
CGN-54 Schneider I-03 AB N 1996 Cologne, Germany NT ⁄UP 42 1-34-14-28-22-35-2
CGN-82 Multi 2 AB Y Ghent, Belgium B 43 1-42-49-10-1-48-23
CGN-68 SCOPE 2 AB N 1995 Miami, FL, USA S-I 44 10-12-1-33-4-29-31
CGN-29 PGS 10508 AB N 1990 Denmark XVIII 45 10-12-30-24-4-9-20
CGN-79 Neustrelitz 1 AB Y 1996 Neustrelitz, Germany NT ⁄UP 46 10-12-4-11-4-29-2
CGN-76 Multi 1 AB Y Freiburg, Germany A 47 10-12-4-11-4-29-35
CGN-51 PGS 14554 AB N Denmark XXIV 48 10-12-4-6-4-33-2
CGN-10 V-12334 AB N 1991 Cologne, Germany XXIII 49 10-19-17-16-4-9-2
CGN-43 St-12084 AB N 1991 Cologne, Germany XXXII 50 10-34-40-26-22-27-2
CGN-45 V-4316 AB N 1991 Cologne, Germany XXII 51 11-12-4-11-1-28-2
CGN-01 PGS 14544 AB Y Denmark XIV 52 12-17-16-1-14-14-7
CGN-13 U-10651 AB N 1991 Cologne, Germany NT ⁄UP 53 13-12-19-6-1-9-2
CGN-31 222 ⁄ 98 AB N 1998 Cologne, Germany NT ⁄UP 54 13-12-32-24-4-9-22
CGN-36 St-20421 AB N 1991 Cologne, Germany X 55 13-33-37-24-4-11-2
CGN-14 M-3789 AB N 1991 Cologne, Germany XXXI 56 14-23-20-1-16-17-13
CGN-16 M-3317 AB N 1991 Cologne, Germany XXVI 57 15-24-4-18-17-19-15
CGN-26 M-2184 AB N 1991 Cologne, Germany NT ⁄UP 58 18-17-28-22-4-4-18
CGN-28 M-12225 I AB N 1991 Cologne, Germany NT ⁄UP 59 19-30-29-23-18-24-19
CGN-65 SCOPE 47 AB Y 1996 Las Vegas, NV, USA S-f 60 2-21-12-32-26-39-2
CGN-33 Berlin 5-8734 AB Y 1996 Berlin, Germany NT ⁄UP 61 20-12-34-24-1-9-2
CGN-34 Multi 25 AB N Freiburg, Germany NT ⁄UP 62 21-31-35-24–1-25-23
CGN-47 St-18748 AB N 1991 Cologne, Germany XVI 63 23-35-3-27-23-30-19
CGN-49 V-17215 AB N 1991 Cologne, Germany NT ⁄UP 64 24-1-42-13-24-32-26
CGN-69 SCOPE 23 AB N 1996 New York, NY, USA NT ⁄UP 65 28-38-45-1-16-40-5
CGN-64 SCOPE 44 AB Y 1995 Las Vegas, NV, USA S-e 66 28-38-45-31-16-30-5
CGN-75 SCOPE 40 AB Y 1995 Iowa City, IO, USA NT ⁄UP 67 29-41-48-11-1-45-10
CGN-12 U-9560 AB N 1991 Cologne, Germany XXXV 68 3-22-18-1-1-16-12
CGN-02 PGS 353 13TU Y 1985 Odense, Denmark III I 1-18-1-15-15-15-8
CGN-22 PGS 4419 13TU N 1991 Denmark I II 1-28-26-20-15-13-1
CGN-73 SCOPE 8 13TU N 1995 Savannah, GA, USA NT ⁄UP III 1-37-44-34-15-43-34
CGN-42 PGS 10716 13TU N 1990 Denmark V IV 10-29-14-21-15-26-6
ACI-19 St-11681 13TU Y 1991 Cologne, Germany IV V 11-16-14-14-13-13-6
ACI-20 St-7961 13TU Y 1991 Cologne, Germany IV V 11-16-14-14-13-13-6
CGN-08 St-20045–90 13TU Y 1990 Cologne, Germany IV V 11-16-14-14-13-13-6
CGN-80 Multi 4 13TU Y Odense, Denmark d VI 11-20-14-20-15-47-6
CGN-67 SCOPE 59 13TU N 1996 Akron, OH, USA NT ⁄UP VII 11-27-14-21-15-36-6
CGN-60 SCOPE 81 13TU Y 1996 Richmond, VA, USA S-b VIII 11-27-14-21-15-38-6
CGN-78 Schneider I-08 13TU Y 1996 Cologne, Germany NT ⁄UP IX 11-27-14-21-15-46-36
CGN-50 PGS 12112 13TU N 1990 Denmark Va X 11-29-14-21-15-26-6
CGN-72 SCOPE 7 13TU N 1995 Savannah, GA, USA NT ⁄UP XI 11-40-47-30-27-42-33
CGN-21 PGS 53937 bb 13TU N Denmark VI XII 16-27-25-19-15-22-19
CGN-24 Schneider VI-10 13TU N 1996 Cologne, Germany NT ⁄UP XIII 17-29-27-21-15-23-6
CGN-32 PGS 9894 13TU N 1991 Denmark II XIV 17-32-33-20-19-13-6
CGN-57 SCOPE 74 13TU Y 1996 Richmond, VA, USA S-a XV 25-27-14-21-15-34-27
CGN-58 SCOPE 79 13TU Y 1996 Richmond, VA, USA NT ⁄UP XVI 26-36-43-20-25-36-28
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rather than in a specific set of strains selected for
validation purposes only. Also, there is currently
no established MLST database for Acinetobacter
genomic species 13TU; thus, all 18 MLST profiles
generated for Acinetobacter genomic species 13TU
isolates were considered to be novel. As observed
previously for A. baumannii [23], the MLST results
were highly concordant with PFGE and RAPD-
PCR typing results, both for A. baumannii and for
Acinetobacter genomic species 13TU isolates.
Therefore, the current MLST scheme appears to
be useful for typing of both species. However,
proper identification to the species level is
required, and both species should be analyzed
separately by MLST if an algorithm such as
eBURST is used, because the differences among
species would not be visible in the eBURST
dataset and could lead to false conclusions.
As suspected from the validation study [23],
the population structure of A. baumannii seems
to be highly diverse; however, because of the
still limited number of isolates that have been
analyzed to date (49 isolates in the database and
54 in the present study), it may be too early to
reach a definitive conclusion. The Ia of 0.716
was lower than in the previous analysis
(Ia = 2.592 [23]), probably reflecting the much
more heterogeneous population of isolates
investigated. Limiting the analysis to only one
representative isolate per ST did not change the
relationship (0.546 vs. 1.393). Generally, clonal
populations are identified by an Ia value that
differs significantly from zero [30]. The value of
this analysis is somewhat limited, since isolates
were selected to reflect diversity rather than as a
representative cross-section of the population. It
Table 1. (Continued)
Isolate
Original
designation Species
Outbreak
(Y ⁄N)
Origin
Year Country
PFGE or
RAPD profile ST Allelic profile
CGN-59 SCOPE 80 13TU Y 1996 Richmond, VA, USA NT ⁄UP XVII 26-36-43-29-25-37-28
CGN-61 SCOPE 83 13TU Y 1996 Richmond, VA, USA NT ⁄UP XVIII 27-37-44-30-25-38-29
aCapital letters designate PFGE patterns described by Bartual et al. [23].
bRoman numerals designate PFGE patterns described by Seifert and Gerner-Smidt [15].
cLower-case letters designate RAPD patterns described by Grundmann et al. [16].
dWith prefix S- for SCOPE isolates described by Wisplinghoff et al. (S-x; [25]); NT ⁄UP, not typed in direct comparison to all other strains used in this study, or unique pattern.
AB, A. baumannii; 13TU, Acinetobacter genomic species 13TU (allele numbers and STs are numbered separately).
STs numbered 22 and above are novel. For the Acinetobacter genomic species 13TU STs, Roman numerals are used to avoid confusion. All Acinetobacter genomic species 13TU
STs are considered to be novel.
ST, sequence type; PFGE or RAPD pattern.
Table 2. eBURST results for the Acinetobacter baumannii isolates used in this study (isolates described previously [23] are
marked in bold)
ST CC FREQ SLV DLV TLV
Average
distance
ST bootstrap
group (%) Subgroup (%)
32 1 1 1 1 1 2.00 0 0
33 1 1 2 1 0 1.33 27 0
46 1 1 2 1 0 1.33 25 0
47 1 1 1 1 1 2.00 0 0
20 2 2 1 1 0 1.50 0 0
22 2 2 2 0 0 1.00 30 0
34 2 1 1 1 0 1.50 0 0
21 3 2 1 0 0 1.00
27 3 1 1 0 0 1.00
35 4 1 1 0 0 1.00
36 4 1 1 0 0 1.00
6 5 1 1 0 0 1.00
10 5 1 1 0 0 1.00
Singletons:
1 2 3 4 5 7 8 9 11 12 13 14 15
16 17 18 19 23 24 25 26 28 29 30 31 37
38 39 40 41 42 43 44 45 48 49 50 51 52
53 54 55 56 57 58 59 60 61 62 63 64 65
66 67 68
ST, sequence type; CC, clonal complex; FREQ, frequency; SLV, single-locus variant; DLV, double-locus variant; TLV, triple-locus variant.
712 Clinical Microbiology and Infection, Volume 14 Number 7, July 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 708–715
appears from the present data that the MLST
scheme has a high discriminative power that
probably exceeds the discrimination among
isolates that is seen with other MLST schemes.
This may reflect the fact that most of the
isolates were selected on the basis of having a
distinct PFGE pattern; nevertheless, isolates of
methicillin-resistant S. aureus with different
PFGE types are often represented by a single
ST [32].
Recent data generated using PCR–electrospray
ionisation mass spectrometry (ESI-MS) revealed
clonal relatedness among most A. baumannii iso-
lates collected from patients treated in US military
hospitals during Operation Iraqi Freedom and the
well-characterized European A. baumannii hospi-
tal clones I–III [33]. Although the possibility of a
common ancestor was considered, no firm epide-
miological link could be established. Similar to
MLST, the PCR ESI-MS method uses eight PCR
products generated from the conserved regions of
the six housekeeping genes efp, trpE, adk, mutY,
fumC and ppa [33]. In contrast to MLST, the mass
spectra of the PCR products, rather than the
sequences, are compared, thereby making it one
of the fastest systems available for typing A. bau-
mannii. Identification of Acinetobacter genomic
species 13TU is also possible; however, typing of
this species by PCR ESI-MS has not yet been
attempted, and further evaluation of this method
is needed to determine its future potential.
Apart from a single instance in which an
identical outbreak strain (ST-19) was recovered
in Nottingham, UK and Cologne, Germany, with
no obvious epidemiological link, no apparent
relatedness was revealed among isolates recov-
ered from outbreaks in different countries in
Europe or in different regions in the USA. In
particular, representatives of European clones I
and II (i.e. ST-12 and ST-6, respectively) were not
found among the isolates investigated. However,
the significance of this finding is somewhat
limited by the fact that most isolates were from
Germany and the USA, and comprised both
hospital outbreak-related and sporadic isolates,
and only a few isolates from other European
countries were included. Further studies should
include isolates that were found in previous
reports to be associated with large multicentre
outbreaks, e.g. those reported from Spain [34],
France [35] and countries in northwestern Europe
[4,36]. The primers described previously enabled
the necessary fragments from all A. baumannii and
Acinetobacter genomic species 13TU isolates tested
to be amplified and sequenced, and species-
specific homologous regions in the seven genes
were revealed. Using UPGMA analysis, these
differences were sufficient to differentiate unam-
biguously between A. baumannii and Acinetobacter
genomic species 13TU isolates.
In conclusion, the MLST scheme appears to
provide a high level of resolution and is a
promising tool for studying the epidemiology
of A. baumannii. The scheme in its current form
can also be used for epidemiological studies of
Acinetobacter genomic species 13TU isolates, for
which a novel database will need to be created.
The usefulness of the MLST scheme for studying
the population structure of A. baumannii, which
appears to be highly diverse, remains to be
determined by studies with a larger number of
isolates from diverse geographical locations.
Fig. 1. Sequences of selected Acinetobacter baumannii and
Acinetobacter genomic species 13TU isolates. Alleles of
gdhB and recA are displayed as examples. Characteristic
differences are displayed in bold font. Only the polymor-
phic sites of the 12 selected isolates are displayed.
Numbers denote positions within the multilocus sequence
typing sequence. 13TU, Acinetobacter genomic spe-
cies 13TU; AB, A. baumannii.
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